Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · IEX Real-Time Price · USD
30.75
+0.07 (0.23%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Supernus Pharmaceuticals Employees
Supernus Pharmaceuticals had 652 employees as of December 31, 2023. The number of employees increased by 40 or 6.54% compared to the previous year.
Employees
652
Change (1Y)
40
Growth (1Y)
6.54%
Revenue / Employee
$916,259
Profits / Employee
-$23,785
Market Cap
1.69B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 652 | 40 | 6.54% |
Dec 31, 2022 | 612 | 37 | 6.43% |
Dec 31, 2021 | 575 | 12 | 2.13% |
Dec 31, 2020 | 563 | 99 | 21.34% |
Dec 31, 2019 | 464 | 16 | 3.57% |
Dec 31, 2018 | 448 | 26 | 6.16% |
Dec 31, 2017 | 422 | 59 | 16.25% |
Dec 31, 2016 | 363 | 19 | 5.52% |
Dec 31, 2015 | 344 | 35 | 11.33% |
Dec 31, 2014 | 309 | 74 | 31.49% |
Dec 31, 2013 | 235 | 42 | 21.76% |
Dec 31, 2012 | 193 | 124 | 179.71% |
Dec 31, 2011 | 69 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Evotec SE | 4,952 |
Alignment Healthcare | 1,536 |
Indivior | 1,164 |
Schrödinger | 867 |
MannKind | 414 |
RxSight | 374 |
Kura Oncology | 142 |
Edgewise Therapeutics | 88 |
SUPN News
- 3 days ago - Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy - GlobeNewsWire
- 2 months ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN - PRNewsWire
- 2 months ago - Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures - GlobeNewsWire
- 2 months ago - Supernus Announces First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America - PRNewsWire
- 3 months ago - Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors - Business Wire